CD19 and acute lymphoblastic leukemia: CAR T-cell therapy has been highly successful for r/r B-cell malignancies, and two CAR T-cell products targeting CD19 are FDA approved for ALL and lymphoma: Tisaglenlecleucel and Axicabtagene ciloleucel [14,15,16].